Tuis207940 • KRX
add
Samsung Biologics Co Ltd
Vorige sluiting
₩796 000,00
Dagwisseling
₩792 000,00 - ₩815 000,00
Jaarwisseling
₩668 000,00 - ₩880 000,00
Markkapitalisasie
57,44 bn KRW
Gemiddelde volume
70,08 k
P/V-verhouding
64,15
Dividend-opbrengs
-
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(KRW) | Mrt. 2024info | J/J-verandering |
---|---|---|
Inkomste | 946,90 mjd | 31,35% |
Bedryfskoste | 197,05 mjd | 32,09% |
Netto inkomste | 179,36 mjd | 26,53% |
Netto winsgrens | 18,94 | -3,66% |
Wins per aandeel | 2,52 k | 26,51% |
EBITDA | 364,72 mjd | 24,72% |
Effektiewe belastingkoers | 25,29% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(KRW) | Mrt. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 2,06 bn | -30,52% |
Totale bates | 16,52 bn | 0,86% |
Totale aanspreeklikheid | 6,51 bn | -10,23% |
Totale ekwiteit | 10,01 bn | — |
Uitstaande aandele | 71,17 m | — |
Prys om te bespreek | 5,66 | — |
Opbrengs op bates | 3,40% | — |
Opbrengs op kapitaal | 4,72% | — |
Kontantvloei
Netto kontantverandering
(KRW) | Mrt. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | 179,36 mjd | 26,53% |
Kontant van bedrywe | 289,84 mjd | -8,49% |
Kontant van beleggings | 584,92 mjd | 49,80% |
Kontant van finansiering | -202,29 mjd | -135,76% |
Netto kontantverandering | 692,14 mjd | 9,63% |
Beskikbare kontantvloei | 660,62 mjd | 245,31% |
Meer oor
Samsung Biologics Co., Ltd. is a South Korean biotechnology company headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, it provides contract development and manufacturing services to the biopharmaceutical industry.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly and AstraZeneca. Samsung Biologics also partnered with Moderna for fill-finish, packaging and labeling of its mRNA vaccine, Spikevax, during the COVID-19 pandemic. Wikipedia
HUB
Gestig
2011
Webwerf
Werknemers
4 284